11 May 2020

Roche today announced that Human Cell Atlas (HCA) founding co-chair Aviv Regev will become the Executive Vice President for Genentech Research and Early Development (gRED) as of 1 August 2020.  She will continue to serve as co-chair of the HCA Organizing Committee with Sarah Teichmann, also an HCA co-founder. 

Aviv stated, “While this development represents a major transition for me personally, with an opportunity to have an even deeper impact on understanding human biology and bringing therapies to patients, it will in no way diminish my involvement and roles with HCA.”

In addition to her role as Executive VP for gRED, Aviv will serve on the Corporate Executive Committee at Roche. She will be based in South San Francisco.